 PARIS and CAMBRIDGE, Mass., Aug. 16, 2021 GLOBE NEWSWIRE -- Biophytis SA NasdaqCM: BPTS, Euronext Growth Paris: ALBPS, a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from COVID-19, today announces the recommendation by the Data Monitoring Committee DMC to continue patient recruitment into part 2 of the COVA study with the protocol unmodified after review of safety data. 